The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector

• MannKind Corporation recently reported that the FDA accepted its supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, a rapid subcutaneous furosemide delivery device for adults with chronic heart failure or chronic kidney disease, with a PDUFA target action date of July 26, 2026.
• If approved, ReadyFlow could meaningfully change at-home management of fluid buildup by cutting administration time from five hours to under 10 seconds while showing bioavailability comparable to intravenous furosemide.
• We’ll now examine how the potential for much faster at-home furosemide delivery could influence MannKind’s broader investment narrative.

Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

MannKind Investment Narrative Recap

To own MannKind, you need to believe its inhaled and drug delivery platforms can expand beyond Afrezza and Tyvaso DPI into additional, durable revenue streams. The FDA’s acceptance of the FUROSCIX ReadyFlow sNDA adds a clear, but longer dated, potential catalyst for 2026, while the near term story still hinges on execution in the core portfolio and managing high debt and operating costs.

The ReadyFlow filing sits alongside MannKind’s shift into consistent profitability, with 2024 revenue of US$285,500,000 and net income of US$27,590,000, followed by positive earnings in each of the first three quarters of 2025. That improving earnings base may matter if ReadyFlow ultimately gains approval and starts to diversify the company’s reliance on Afrezza and Tyvaso DPI royalties.

Yet, despite these opportunities, investors should also be aware that...

Read the full narrative on MannKind (it's free!)

MannKind's narrative projects $437.5 million revenue and $70.4 million earnings by 2028.

Uncover how MannKind's forecasts yield a $9.39 fair value, a 58% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates span roughly US$7.42 to US$18.13 per share, underscoring how differently individual investors view MannKind. As you weigh those views against MannKind’s reliance on a limited core portfolio, it can be helpful to explore multiple assessments of how that concentration might affect future performance.

Explore 4 other fair value estimates on MannKind - why the stock might be worth over 3x more than the current price!

Build Your Own MannKind Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your MannKind research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free MannKind research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MannKind's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com